Advertisement

SABCS 2022: monarchE Trial of Abemaciclib Plus ET for HR-Positive, HER2-Negative, Node-Positive, High-Risk Early Breast Cancer
Posted: 01/03/2023 | By: Chase Doyle

An interim analysis of the monarchE trial of abemaciclib plus endocrine therapy to assess overall survival as well as invasive disease–free survival and distant relapse–free survival with additional follow-up in patients with hormone receptor (HR)-positive, HER2-negative, node-positive, high-risk early breast cancer was published in The Lancet Oncology and presented at the 2022 San Antonio Breast Cancer Symposium (Abstract GS1-09).

Question 1 of 5

In the phase III monarchE trial, what was the absolute difference in invasive disease–free survival at 4 years in the abemaciclib plus endocrine therapy group vs the endocrine therapy alone group?

Choose 1